 Home > Active Ingredient News > Antitumor Therapy > Cancers: The plasma levels of CEA, CA19-9, IL-6, CRP, and YKL-40 in patients with colorectal cancer (CRC) after adjuvant chemotherapy can predict the advancement and prognosis of disease progression

Cancers: The plasma levels of CEA, CA19-9, IL-6, CRP, and YKL-40 in patients with colorectal cancer (CRC) after adjuvant chemotherapy can predict the advancement and prognosis of disease progression

 Last Update: 2021-08-13
 Source: Internet
 Author: User

Tags

what cancer patients eat

what 2 5 1 3

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Of colorectal cancer (CRC) is a common digestive one tract

The study included 147 patients with stage II-IV colorectal cancer (CRC) in the phase III study LIPSYT (ISRCTN98405441), who received 24-week 5-FU-based adjuvant chemotherapy

Studies have shown that CEA (HR=5.

DFS

The increased levels of IL-6 (HR=3.

A corrected multivariate analysis found that elevated CEA and IL-6 after adjuvant chemotherapy were associated with poor DFS, while IL-6 and CRP were associated with poor OS

Multi-factor DFS and OS related factors analysis

For patients with normal CEA (<5 µ g/L), elevated IL-6 is associated with poor DFS (HR=3.

CEA normal IL-6 increased DFS and OS comparison

The lead time of disease progression is defined as the time from the first discovery of an increase to imaging or clinical diagnosis of local progression or distant metastasis

The lead time of disease progression is defined as the time from the first discovery of an increase to imaging or clinical diagnosis of local progression or distant metastasis
.
CEA was 7.
8 months, CA199 was 10.
0 months, IL-6 was 21.
8 months, CRP was 10.
2 months, and YKL-40 was 53.
1 months
.
The lead time when any one of the five indicators rises is 27.
3 months
.
The diagnosis of CEA was 7.
8 months, CA199 was 10.
0 months, IL-6 was 21.
8 months, CRP was 10.
2 months, and YKL-40 was 53.
1 months
.
The lead time when any one of the five indicators rises is 27.
3 months
.

Lead time for predicting disease progression

In summary, elevated CEA, IL-6, and CRP levels after adjuvant chemotherapy are associated with poor disease-free survival (DFS), while IL-6 and CRP levels are associated with poor overall survival (OS)
.
CEA has the shortest lead time for predicting disease progression
.
Elevated CEA, IL-6, and CRP levels after adjuvant chemotherapy are associated with poor disease-free survival (DFS), while IL-6 and CRP levels are associated with poor overall survival (OS)
.
CEA has the shortest lead time for predicting disease progression
.
Elevated CEA, IL-6, and CRP levels after adjuvant chemotherapy are associated with poor disease-free survival (DFS), while IL-6 and CRP levels are associated with poor overall survival (OS)
.
CEA has the shortest lead time for predicting disease progression
.

Original source:

Lehtomäki, K.
; Mustonen,H.
; Kellokumpu-Lehtinen, P.
-L.
; et al.
Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer.
Cancers 2021, 13, 3892.
https://doi.
org/10.
3390/cancers13153892.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.